PHIA Koninklijke Philips N.V.

Philips named a Derwent Top 100 Global Innovator for the 7th consecutive year

Philips named a Derwent Top 100 Global Innovator for the 7th consecutive year

February 24, 2020

Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, has again been recognized as a Derwent Top 100 Global Innovator™ in Clarivate Analytics’ annual analysis of the global innovation ecosystem.  The identifies the world’s most innovative organizations, those that successfully develop valuable patented inventions with strong commercialization potential based on their market reach and impact on other downstream inventions [1]. Philips has successively won a place on this prestigious list for the last seven years.

“Philips’ innovation strength is powering our drive to provide integrated solutions that improve people's health across the health continuum,” said Frans van Houten, CEO of Royal Philips. “I am pleased that we have once again been recognized, for the 7th consecutive year, as a Derwent Top 100 Global Innovator by Clarivate Analytics. I remain convinced that our ongoing commitment to innovation and R&D, combined with our sense of purpose and culture of customer centricity, will continue to drive our mission to make the world healthier and more sustainable.”

Philips’ EUR 1.9 billion R&D program has resulted in the introduction of many successful innovations, including the new imaging platform for radiology departments, helping them to improve the patient and staff experience, enable smart clinical decision-making and increase efficiency, and the 1.5T MRI system, which enables helium-free operations while delivering superb image quality. Philips also launched the new and patient monitors, which feature a wide range of measurements and analytics together with innovative new cybersecurity capabilities. In oral care, the company rolled out its connected Sonicare ExpertClean – a new smart power toothbrush that delivers superior oral care results with sonic technology and deep clean brushing modes.

The Derwent Top 100 Global Innovators™ 2020 report and a full list of the Top 100 organizations named in it can be found .

[1] The Derwent Top 100 Global Innovators tracks innovation based on four indicators: 1. Volume: The organization must have had at least 100 granted inventions (and more than 500 filed in total) in the past five years. 2. Influence: The level of downstream impact by being highly cited externally by other organizations, and measured via the Derwent Patent Citations Index over the last five years, excluding citations from themselves. 3. Success: A high ratio of success in obtaining patent grants. 4. Globalization: The level of investment of a patent applicant in their invention, as tracked via the process of pursuing protection in all four of the key market patent offices of China, Europe, Japan, and the United States.

For further information, please contact:

Ben Zwirs

Philips Global Press Office

Tel.:

E-mail:

Leandro Mazzoni

Philips Investor Relations

Tel.:

E-mail:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 80,000 employees with sales and services in more than 100 countries. News about Philips can be found at .

Attachments

EN
24/02/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips publishes its Annual Report 2025

Philips publishes its Annual Report 2025 February 19, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2025. Philips’ Annual Report 2025 will be on the agenda of the Annual General Meeting of Shareholders (AGM), to be held on May 8, 2026. The convocation notice and the agenda, including explanatory notes, for the AGM will be published in due course. Philips filed the Annual Report 2025 with the Netherlands Authority for the Financial Markets (AFM) in European Single Electronic Format (ESEF) and expects to f...

 PRESS RELEASE

Philips introduces InkSpace Imaging’s Snuggle™ flexible pediatric MRI ...

Philips introduces InkSpace Imaging’s Snuggle™ flexible pediatric MRI coil for its 3.0T MR systems, helping to enhance imaging precision, efficiency and comfort February 12, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the availability of the InkSpace Imaging Snuggle™ pediatric body array coil for Philips 3.0T MRI systems. Designed specifically for pediatric patients, the Snuggle coil has been optimized and validated for use with Philips 3.0T MRI systems, bringing enhanced comfort for children and efficient, high-quality i...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

ABN Amro: Miss but strong capital, good set of results / Ahold Delhaize: Strong 4Q25 but no major surprise on FY26 adj. EPS guidance / Alfen: No recovery yet and another transitional year / BAM Group: Preview: 2026 outlook the key item / Econocom: Better REBITA, net debt, but EBIT below, much lower net profit, dividend halved, 2026-28 guidance postponed to “medium term” / Exor: Ferrari 4Q25 and 2026 guidance beat / Gecina: Results and guidance in line, DPS set to grow over 2026-30 / Heineken: No...

Oscar Rodriguez
  • Oscar Rodriguez

PHILIPS: RDOS. 4T’25 Y CAMBIO DE P.O. AL ALZA (ANÁLISIS BANCO SABADELL...

Rdos. 4T’25 vs 4T’24: Ventas: 5.097 M euros (+1,1% vs -0,9% BS(e) y -1,0% consenso); EBITA Aj.: 770 M euros (+13,4% vs +0,6% BS(e) y -1,0% consenso); BDI: 397 M euros (-333 M euros en 2024 vs 275 M euros BS(e) y 276 M euros consenso); Rdos. 2025 vs 2024: Ventas: 17.834 M euros (-1,0% vs -1,6% BS(e) y -1,6% consenso); EBITA Aj.: 2.195 M euros (+5,7% vs +1,5% BS(e) y +1,0% consenso); BDI: 897 M euros (-698 M euros en 2024 vs 775 M euros BS(e) y 776 M euros consenso).

ResearchPool Subscriptions

Get the most out of your insights

Get in touch